Stability indicating ion-pair HPLC method for the determination of risedronate in a commercial formulation

Citation:
ALUOCH DRAUSTINOCHIENG. "Stability indicating ion-pair HPLC method for the determination of risedronate in a commercial formulation.". In: Journal of Liquid Chromatography and Related Technologies, 27(17), 2799-2813 (2004). Taylor & Francis, Colchester, ROYAUME-UNI (1996) (Revue); 2004.

Abstract:

Aluoch, A., Tatini, R., Parsons, D. M., Sadik, O. A. A simple, rapid, and reproducible analytical procedure has been developed for the assay of risedronate in pharmaceutical dosage forms. The method is based on ion-pair liquid chromatography with UV detection. 2 Separation is performed on an Eclipse XDB C-18 (4.6 x 150 mm(2), 3.5 mum particles) column, using 5 mM tetrabutylammonium phosphate as counter-ion in the mobile phase. The proposed method was extensively validated according to ICH guidelines for the assay determination. A linear relationship was found in the concentration range studied from 50 to 150 mug risedronate sodium per 25 muL injection. The method precision was below 1.2% relative standard deviation (RSD) (n = 9). The mean recovery of risedronate from commercial tablets was found to be in the range of 99.3-100.6%. The limit of detection (LOD) and limit of quantification (LOQ) of risedronate were found to be 30 and 100 ng, respectively. Since the method is stability indicating, it is also well suited for shelf-life studies of risedronate pharmaceutical preparations.

Notes:

n/a

Website

UoN Websites Search